Loading…
Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019
Purpose To determine the difference in the burden of benign prostatic hyperplasia (BPH) between China and the United States from 1990 to 2019. Methods The prevalence, incidence, Years Lived with Disability (YLD), and their age-standardized rates for BPH in China and USA from 1990 to 2019 were based...
Saved in:
| Published in: | World journal of urology 2023-12, Vol.41 (12), p.3629-3634 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c375t-78677f364c1755b00e4211c1bcd998808c4748fbac9202580690a9e4bb531c713 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c375t-78677f364c1755b00e4211c1bcd998808c4748fbac9202580690a9e4bb531c713 |
| container_end_page | 3634 |
| container_issue | 12 |
| container_start_page | 3629 |
| container_title | World journal of urology |
| container_volume | 41 |
| creator | Liu, Dingwen Li, Cheng Li, Youyou Zhou, Liang Li, Jiaren Wang, Yichuang Wan, Xiaomin Zhou, Lei Wang, Long |
| description | Purpose
To determine the difference in the burden of benign prostatic hyperplasia (BPH) between China and the United States from 1990 to 2019.
Methods
The prevalence, incidence, Years Lived with Disability (YLD), and their age-standardized rates for BPH in China and USA from 1990 to 2019 were based on the Global Burden of Disease Study 2019 (GBD 2019). The annual percentage changes (APC) of the age-standardized incidence rate (ASIR) and the age-standardized YLD rates (ASYR) were calculated using joinpoint regression analysis. The YLD numbers of six urinary tract diseases were also compared in both countries.
Results
The absolute burden of BPH increased continuously in both countries, but it was much higher in China than in the United States. The ASIR and ASYR of BPH decreased in China but remained stable or decreased slightly in the United States. BPH incidence and YLD rates decreased in all age groups in China from 1990 to 2019. In the USA, they varied by age group. BPH caused more YLD number than any other urinary tract disease in China. In the USA, prostate cancer (PCa) caused more YLDs than BPH.
Conclusions
This research reveals marked BPH burden differences between China and the US (1990–2019). China's higher burden necessitates targeted interventions, while unique trends in both countries demand tailored strategies. These insights enhance understanding of BPH dynamics, informing effective interventions across diverse contexts. |
| doi_str_mv | 10.1007/s00345-023-04658-8 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2877385358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2896128837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-78677f364c1755b00e4211c1bcd998808c4748fbac9202580690a9e4bb531c713</originalsourceid><addsrcrecordid>eNp9kT1v1TAUhi0EoqXtH-iALLF0CRzbceyM7S0UpEoM0NmynZNeV7lOaieq7sRfxyWFIgYmfz3nObZfQk4ZvGcA6kMGELWsgIsK6kbqSr8gh6wWotKKNy__mh-QNznfATDVgHxNDoTSgjGpDsmPC4zhNtIpjXm2c_B0u58wTYPNwVK3pA4j9eNusinkMVKH8wOWrc02REtt7OhNDDN29FupxkydzWVRwHmL9GoYnR3oxWoZe3oZMhagwEu3pxxYe0xe9XbIePI0HpGbTx-_bz5X11-vvmzOrysvlJwrpRuletHUnikpHQDWnDHPnO_aVmvQvla17p31LQcuNTQt2BZr56RgXjFxRM5Wb3no_YJ5NruQPQ6DjTgu2XCtlNBSSF3Qd_-gd-OSYrldodqGca2FKhRfKV9-LifszZTCzqa9YWAe4zFrPKbEY37FYx7Vb5_Ui9th96fkdx4FECuQy1G8xfTc-z_an1FQmV0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2896128837</pqid></control><display><type>article</type><title>Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019</title><source>Springer Nature</source><creator>Liu, Dingwen ; Li, Cheng ; Li, Youyou ; Zhou, Liang ; Li, Jiaren ; Wang, Yichuang ; Wan, Xiaomin ; Zhou, Lei ; Wang, Long</creator><creatorcontrib>Liu, Dingwen ; Li, Cheng ; Li, Youyou ; Zhou, Liang ; Li, Jiaren ; Wang, Yichuang ; Wan, Xiaomin ; Zhou, Lei ; Wang, Long</creatorcontrib><description>Purpose
To determine the difference in the burden of benign prostatic hyperplasia (BPH) between China and the United States from 1990 to 2019.
Methods
The prevalence, incidence, Years Lived with Disability (YLD), and their age-standardized rates for BPH in China and USA from 1990 to 2019 were based on the Global Burden of Disease Study 2019 (GBD 2019). The annual percentage changes (APC) of the age-standardized incidence rate (ASIR) and the age-standardized YLD rates (ASYR) were calculated using joinpoint regression analysis. The YLD numbers of six urinary tract diseases were also compared in both countries.
Results
The absolute burden of BPH increased continuously in both countries, but it was much higher in China than in the United States. The ASIR and ASYR of BPH decreased in China but remained stable or decreased slightly in the United States. BPH incidence and YLD rates decreased in all age groups in China from 1990 to 2019. In the USA, they varied by age group. BPH caused more YLD number than any other urinary tract disease in China. In the USA, prostate cancer (PCa) caused more YLDs than BPH.
Conclusions
This research reveals marked BPH burden differences between China and the US (1990–2019). China's higher burden necessitates targeted interventions, while unique trends in both countries demand tailored strategies. These insights enhance understanding of BPH dynamics, informing effective interventions across diverse contexts.</description><identifier>ISSN: 1433-8726</identifier><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-023-04658-8</identifier><identifier>PMID: 37831157</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adenomatous polyposis coli ; Age ; China - epidemiology ; Disease ; Genital diseases ; Global Burden of Disease ; Humans ; Hyperplasia ; Incidence ; Male ; Medicine ; Medicine & Public Health ; Nephrology ; Oncology ; Original Article ; Prevalence ; Prostate cancer ; Prostatic Hyperplasia - epidemiology ; Quality-Adjusted Life Years ; United States - epidemiology ; Urinary tract ; Urinary tract diseases ; Urogenital system ; Urology</subject><ispartof>World journal of urology, 2023-12, Vol.41 (12), p.3629-3634</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-78677f364c1755b00e4211c1bcd998808c4748fbac9202580690a9e4bb531c713</citedby><cites>FETCH-LOGICAL-c375t-78677f364c1755b00e4211c1bcd998808c4748fbac9202580690a9e4bb531c713</cites><orcidid>0000-0003-4583-2428</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37831157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Dingwen</creatorcontrib><creatorcontrib>Li, Cheng</creatorcontrib><creatorcontrib>Li, Youyou</creatorcontrib><creatorcontrib>Zhou, Liang</creatorcontrib><creatorcontrib>Li, Jiaren</creatorcontrib><creatorcontrib>Wang, Yichuang</creatorcontrib><creatorcontrib>Wan, Xiaomin</creatorcontrib><creatorcontrib>Zhou, Lei</creatorcontrib><creatorcontrib>Wang, Long</creatorcontrib><title>Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Purpose
To determine the difference in the burden of benign prostatic hyperplasia (BPH) between China and the United States from 1990 to 2019.
Methods
The prevalence, incidence, Years Lived with Disability (YLD), and their age-standardized rates for BPH in China and USA from 1990 to 2019 were based on the Global Burden of Disease Study 2019 (GBD 2019). The annual percentage changes (APC) of the age-standardized incidence rate (ASIR) and the age-standardized YLD rates (ASYR) were calculated using joinpoint regression analysis. The YLD numbers of six urinary tract diseases were also compared in both countries.
Results
The absolute burden of BPH increased continuously in both countries, but it was much higher in China than in the United States. The ASIR and ASYR of BPH decreased in China but remained stable or decreased slightly in the United States. BPH incidence and YLD rates decreased in all age groups in China from 1990 to 2019. In the USA, they varied by age group. BPH caused more YLD number than any other urinary tract disease in China. In the USA, prostate cancer (PCa) caused more YLDs than BPH.
Conclusions
This research reveals marked BPH burden differences between China and the US (1990–2019). China's higher burden necessitates targeted interventions, while unique trends in both countries demand tailored strategies. These insights enhance understanding of BPH dynamics, informing effective interventions across diverse contexts.</description><subject>Adenomatous polyposis coli</subject><subject>Age</subject><subject>China - epidemiology</subject><subject>Disease</subject><subject>Genital diseases</subject><subject>Global Burden of Disease</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Incidence</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prevalence</subject><subject>Prostate cancer</subject><subject>Prostatic Hyperplasia - epidemiology</subject><subject>Quality-Adjusted Life Years</subject><subject>United States - epidemiology</subject><subject>Urinary tract</subject><subject>Urinary tract diseases</subject><subject>Urogenital system</subject><subject>Urology</subject><issn>1433-8726</issn><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kT1v1TAUhi0EoqXtH-iALLF0CRzbceyM7S0UpEoM0NmynZNeV7lOaieq7sRfxyWFIgYmfz3nObZfQk4ZvGcA6kMGELWsgIsK6kbqSr8gh6wWotKKNy__mh-QNznfATDVgHxNDoTSgjGpDsmPC4zhNtIpjXm2c_B0u58wTYPNwVK3pA4j9eNusinkMVKH8wOWrc02REtt7OhNDDN29FupxkydzWVRwHmL9GoYnR3oxWoZe3oZMhagwEu3pxxYe0xe9XbIePI0HpGbTx-_bz5X11-vvmzOrysvlJwrpRuletHUnikpHQDWnDHPnO_aVmvQvla17p31LQcuNTQt2BZr56RgXjFxRM5Wb3no_YJ5NruQPQ6DjTgu2XCtlNBSSF3Qd_-gd-OSYrldodqGca2FKhRfKV9-LifszZTCzqa9YWAe4zFrPKbEY37FYx7Vb5_Ui9th96fkdx4FECuQy1G8xfTc-z_an1FQmV0</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Liu, Dingwen</creator><creator>Li, Cheng</creator><creator>Li, Youyou</creator><creator>Zhou, Liang</creator><creator>Li, Jiaren</creator><creator>Wang, Yichuang</creator><creator>Wan, Xiaomin</creator><creator>Zhou, Lei</creator><creator>Wang, Long</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4583-2428</orcidid></search><sort><creationdate>20231201</creationdate><title>Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019</title><author>Liu, Dingwen ; Li, Cheng ; Li, Youyou ; Zhou, Liang ; Li, Jiaren ; Wang, Yichuang ; Wan, Xiaomin ; Zhou, Lei ; Wang, Long</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-78677f364c1755b00e4211c1bcd998808c4748fbac9202580690a9e4bb531c713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenomatous polyposis coli</topic><topic>Age</topic><topic>China - epidemiology</topic><topic>Disease</topic><topic>Genital diseases</topic><topic>Global Burden of Disease</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Incidence</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prevalence</topic><topic>Prostate cancer</topic><topic>Prostatic Hyperplasia - epidemiology</topic><topic>Quality-Adjusted Life Years</topic><topic>United States - epidemiology</topic><topic>Urinary tract</topic><topic>Urinary tract diseases</topic><topic>Urogenital system</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Dingwen</creatorcontrib><creatorcontrib>Li, Cheng</creatorcontrib><creatorcontrib>Li, Youyou</creatorcontrib><creatorcontrib>Zhou, Liang</creatorcontrib><creatorcontrib>Li, Jiaren</creatorcontrib><creatorcontrib>Wang, Yichuang</creatorcontrib><creatorcontrib>Wan, Xiaomin</creatorcontrib><creatorcontrib>Zhou, Lei</creatorcontrib><creatorcontrib>Wang, Long</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Dingwen</au><au>Li, Cheng</au><au>Li, Youyou</au><au>Zhou, Liang</au><au>Li, Jiaren</au><au>Wang, Yichuang</au><au>Wan, Xiaomin</au><au>Zhou, Lei</au><au>Wang, Long</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>41</volume><issue>12</issue><spage>3629</spage><epage>3634</epage><pages>3629-3634</pages><issn>1433-8726</issn><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Purpose
To determine the difference in the burden of benign prostatic hyperplasia (BPH) between China and the United States from 1990 to 2019.
Methods
The prevalence, incidence, Years Lived with Disability (YLD), and their age-standardized rates for BPH in China and USA from 1990 to 2019 were based on the Global Burden of Disease Study 2019 (GBD 2019). The annual percentage changes (APC) of the age-standardized incidence rate (ASIR) and the age-standardized YLD rates (ASYR) were calculated using joinpoint regression analysis. The YLD numbers of six urinary tract diseases were also compared in both countries.
Results
The absolute burden of BPH increased continuously in both countries, but it was much higher in China than in the United States. The ASIR and ASYR of BPH decreased in China but remained stable or decreased slightly in the United States. BPH incidence and YLD rates decreased in all age groups in China from 1990 to 2019. In the USA, they varied by age group. BPH caused more YLD number than any other urinary tract disease in China. In the USA, prostate cancer (PCa) caused more YLDs than BPH.
Conclusions
This research reveals marked BPH burden differences between China and the US (1990–2019). China's higher burden necessitates targeted interventions, while unique trends in both countries demand tailored strategies. These insights enhance understanding of BPH dynamics, informing effective interventions across diverse contexts.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37831157</pmid><doi>10.1007/s00345-023-04658-8</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4583-2428</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1433-8726 |
| ispartof | World journal of urology, 2023-12, Vol.41 (12), p.3629-3634 |
| issn | 1433-8726 0724-4983 1433-8726 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2877385358 |
| source | Springer Nature |
| subjects | Adenomatous polyposis coli Age China - epidemiology Disease Genital diseases Global Burden of Disease Humans Hyperplasia Incidence Male Medicine Medicine & Public Health Nephrology Oncology Original Article Prevalence Prostate cancer Prostatic Hyperplasia - epidemiology Quality-Adjusted Life Years United States - epidemiology Urinary tract Urinary tract diseases Urogenital system Urology |
| title | Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A17%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benign%20prostatic%20hyperplasia%20burden%20comparison%20between%20China%20and%20United%20States%20based%20on%20the%20Global%20Burden%20of%20Disease%20Study%202019&rft.jtitle=World%20journal%20of%20urology&rft.au=Liu,%20Dingwen&rft.date=2023-12-01&rft.volume=41&rft.issue=12&rft.spage=3629&rft.epage=3634&rft.pages=3629-3634&rft.issn=1433-8726&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-023-04658-8&rft_dat=%3Cproquest_cross%3E2896128837%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-78677f364c1755b00e4211c1bcd998808c4748fbac9202580690a9e4bb531c713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2896128837&rft_id=info:pmid/37831157&rfr_iscdi=true |